en · de · es · fr · pt
methods-notes.peptides4088.com › Topic › Thymosin Beta-4 Fragment Background — Field Notes

Thymosin Beta-4 Fragment Background — Field Notes

By Editorial Desk · published 2026-02-21 · last reviewed 2026-04-12 · Topic

The short version of actin binding fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-04-12 and is reviewed periodically as new material appears.

Thymosin Beta-4 Fragment Background

TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.

Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.

TB-500 Identity and Molecular Background

Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.

Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.

Tb-500 at a glance

PropertyValueNotes
Molecular classSynthetic peptideN-terminal fragment of thymosin beta-4
Residue countSevenSequence LKKTETQ
Approximate mass889 DaAcetylated seven-residue peptide
Common synonymsTB4 fragment, TB500Not identical to full-length TB4
Reported activityActin bindingObserved mainly in cell-free systems

Handling Storage And Analysis

Identity and purity are checked with reversed-phase high-performance liquid chromatography, which separates the target sequence from truncated or deletion analogues, and with mass spectrometry, which confirms the expected molecular mass. Amino acid analysis and peptide mapping give orthogonal confirmation but are used less often outside specialist laboratories. Counter-ion content varies: material purified on trifluoroacetic acid gradients retains trifluoroacetate, and ion exchange can convert the salt form. Residual water and solvent are measured by Karl Fischer titration or thermogravimetric analysis, and any purity figure should be read together with the method used to obtain it.

Lyophilised peptide powders are hygroscopic, and the fragment absorbs atmospheric moisture when a vial is opened at room temperature. Weighing and aliquoting are normally done quickly in a dry environment, and stock solutions are divided into single-use portions before freezing. Repeated freeze-thaw cycles are avoided because they promote aggregation and can shift the measured content of a vial. These practices are general to synthetic peptides rather than unique to this sequence, but they matter more for short chains kept for long periods.

The seven-residue chain carries several polar and charged side chains, so it dissolves readily in water and in aqueous buffers near neutral pH. No cysteine is present, so disulphide formation is not a concern and reducing agents are unnecessary. Dilute ammonium hydroxide or acetonitrile-water mixtures are sometimes used for stock solutions when initial dissolution is slow. Strongly alkaline conditions and prolonged contact with oxidising agents are avoided because they can modify lysine-containing stretches, and haze in solution usually signals incomplete dissolution or aggregated material.

Related pages on this site

Research Framing and Evidence Base

Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.

Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.

Supporting material

Сорокин) "Rugby" (Регби) in English translation of Great Soviet Encyclopedia (Progress Publishers, Moscow, 1978) Starmer-Smith, Nigel (ed) Rugby - A Way of Life, An Illustrated History of Rugby (Lennard Books, 1986 ISBN 0-7126-2662-X) Thau, Chris Soviet Rugby in Starmer-Smith, Nigel & Robertson, Ian (eds) The Whitbread Rugby World '89 (Lennard Books, 1988 ISBN 1-85291-038-0) Thau, Chris Soviet Students in Starmer-Smith, Nigel & Robertson, Ian (eds) The Whitbread Rugby World '90 (Lennard Books, 1989 ISBN ) The Ultimate Encyclopaedia of Rugby, (Carlton Books, 1997 ISBN 1-85868-076-X) Dancing On Our Bones: New Zealand, South Africa, Rugby and Racism by Trevor Richards (Bridget Williams Books, 1999). The author was one of a small group of people who founded Halt All Racist Tours (HART) in Auckland in 1969 and worked for the organisation for many years, serving as chair (1969–1980) and international secretary (1980–1985).

The main gas supply for surface-supplied diving can be from high pressure bulk storage cylinders. When the storage cylinders are relatively portable this is known as a scuba replacement system in the commercial diving industry. The application is versatile and can ensure high quality breathing gas in places where atmospheric air is too contaminated to use through a normal low pressure compressor filter system, and is easily adaptable to a mixed gas supply and oxygen decompression provided that the breathing apparatus and gas supply system are compatible with the mixtures to be used. Scuba replacement is often used from smaller diving support vessels, for emergency work, and for hazmat diving. Mixed breathing gases are provided from high pressure bulk storage systems for saturation diving, but these are less portable, and generally involve manifolded racks of cylinders of approximately 50 litres water capacity arranged as quads and even larger racks of high pressure tubes. If gas reclaim systems are used, the reclaimed gas is scrubbed of carbon dioxide, filtered of other contaminants, and recompressed into high pressure cylinders for interim storage, ans is generally blended with oxygen or helium to make up the required mix for the next dive before re-use.

The fundamental process in photoionization is the absorption of a high-energy photon by the molecule and subsequent ejection of an electron. In direct APPI, this process occurs for the analyte molecule, forming the molecular radical cation M•+. The analyte radical cation can be detected as M•+ or it can react with surrounding molecules and be detected as another ion. The most common reaction is the abstraction of a hydrogen atom from the abundant solvent to form the stable [M+H]+ cation, which is usually the observed ion. In dopant-APPI (or photoionization-induced APCI), a quantity of photoionizable molecules (e.g., toluene or acetone) is introduced into the sample stream to create a source of charge carriers. Use of a photoionizable solvent can also achieve the same effect. The dopant or solvent ions can then react with neutral analyte molecules via proton transfer or charge exchange reactions. The above table simplifies the dopant process. In fact, there may be extensive ion-molecule chemistry between dopant and solvent before the analyte becomes ionized. APPI can also produce negative ions by creating a high abundance of thermal electrons from dopant or solvent ionization or by photons striking metal surfaces in the ionization source. The cascade of reactions that can lead to M− or dissociative negative ions [M-X]− often involve O2 as an electron charge carrier. Examples of negative ionization mechanisms include: Direct or dopant-assisted negative ion APPI

=== Dispute with Vivendi === On September 20, 2004, GameSpot reported that Sierra's parent company, Vivendi Universal Games, was in a legal battle with Valve over the distribution of Half-Life 2 to cyber cafés. Cyber cafés were important for the gaming market in Asia, where PC and broadband penetration per capita were much lower in most territories. According to Vivendi, the distribution contract they signed with Valve included cyber cafés. This would mean that only Vivendi could distribute Half-Life 2 to cyber cafés — not Valve through the Steam system. On November 29, 2004, Judge Thomas S. Zilly, of U.S. Federal District Court in Seattle, Washington, ruled that Vivendi and its affiliates were not authorized to distribute (directly or indirectly) Valve games through cyber cafés for pay-to-play activities according to the parties' current publishing agreement. Zilly also ruled in favor of the Valve motion regarding the contractual limitation of liability, allowing Valve to recover copyright damages for any infringement as allowed by law without regard to the publishing agreement's limitation of liability clause. On April 29, 2005, Valve and Vivendi announced a settlement. Vivendi would cease distributing all retail packaged versions of Valve games by August 31, 2005. Vivendi was also to notify distributors and cyber cafés that had been licensed by Vivendi that only Valve had the authority to distribute cyber café licenses; their licenses were revoked and switched to Valve's.

Sources: en.wikipedia.org

Notes from published material

=== Conference === WOSM's conference is its general meeting of member organizations' representatives which meet every three years, hosted by a member association. Each member organizations may send six delegates. The conference is usually preceded by the World Scout Youth Forum.

One weakness of these measures is that they are not good indicators of liver vitamin A stores as retinyl esters in hepatic stellate cells. The amount of vitamin A leaving the liver, bound to retinol binding protein (RBP), is under tight control as long as there are sufficient liver reserves. Only when liver content of vitamin A drops below approximately 20 μg/gram will concentration in the blood decline.

As of this edit, this article uses content from "2.A.17 The Proton-dependent Oligopeptide Transporter (POT/PTR) Family", which is licensed in a way that permits reuse under the Creative Commons Attribution-ShareAlike 3.0 Unported License, but not under the GFDL. All relevant terms must be followed.

Portuguese cuisine is influenced by both the Mediterranean and Atlantic diets. Seafood, brassicas, potatoes, bread, dairy, and olive oil are traditional staples. Bacalhau has such a broad presence in Portugal that it is considered a national dish, along with the pastel de nata. Traditional Portuguese sweets are known as conventual sweets. Large quantities of sugar and eggs are used. Popular Portuguese beverages include its wines, a craft that is well establish since the 7th century, and of which are such examples as Port and Madeira. Beer has been brewed in Portugal since the Chalcolithic. Tea has been produced on São Miguel Island since the 19th century.

== Legality == Plant breeding is subject to a different set of rules and regulations, at times contradictory. The International Union for the Protection of New Varieties of Plants (UPOV Convention) grants limited proprietary rights to breeders over their seeds, under certain conditions. In parallel, and often in a conflicting way, a series of dispositions aiming to fight against biopiracy require breeders to prove that the free, prior and informed consent was obtained from the communities (often Indigenous peoples or peasant communities) from where the seeds used to breed the new variety originates. This is the case in particular of the Nagoya Protocol, a treaty complementing the Convention on Biological Diversity, in force since 2014 (2017 in the European Union). In 2024, the GRATK Treaty was adopted, preventing national patent offices from granting patents based on biopiracy. Patent applicants relying on Cannabis strains will have to disclose the origin of the variety, which often entails compliance under the Nagoya protocol or other similar mechanisms of Access and Benefit Sharing Agreement.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.

What activity is attributed to this sequence?

The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.

Is there a standard purity specification?

Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.

What is TB-500?

TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.

Network